Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-Glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2)

Journal of Pharmacology and Experimental Therapeutics

Volumn 337, Issue 2, 2011, Pages 423-432

  Shen, H ^a   Lee, F Y ^a   Gan, J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CHRYSIN; COMPLEMENTARY DNA; CYCLOSPORIN A; DOCETAXEL; ELACRIDAR; EPOTHILONE B; FUMITREMORGIN C; GLYCOPROTEIN P; IXABEPILONE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PRAZOSIN; VERAPAMIL; VERLUKAST; VINBLASTINE;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL TRANSPORT; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; DRUG TARGETING; DRUG TRANSPORT; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; MICROTUBULE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE; CELL SURVIVAL; DOGS; DRUG RESISTANCE, NEOPLASM; EPITHELIUM; EPOTHILONES; HUMANS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; TAXOIDS; TRANSFECTION; TUBULIN MODULATORS;

EID: 79955028599     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.175604     Document Type: Article

References (39)

1. Arbuck SG, Christian MC, Fisherman JS, Cazenave LA, Sarosy G, Suffness M, Adams J, Canetta R, Cole KE, and Friedman MA (1993) Clinical development of Taxol. J Natl Cancer Inst Monogr 15:11-24.
2. Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JH, Beijnen JH, and van Tellingen O (2002) Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 62:6158-6164. (Pubitemid 35244466)
3. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, and Woods CM (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325-2333.
4. Borst P and Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537-592. (Pubitemid 34800230)
5. Brouty-Boyé D, Kolonias D, Wu CJ, Savaraj N, and Lampidis TJ (1995) Relationship of multidrug resistance to rhodamine-123 selectivity between carcinoma and normal epithelial cells: Taxol and vinblastine modulate drug efflux. Cancer Res 55: 1633-1638.
6. Dumontet C, Jordan MA, and Lee FF (2009) Ixabepilone: Targeting III-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 8:17-25.
7. Guo B, Villeneuve DJ, Hembruff SL, Kirwan AF, Blais DE, Bonin M, and Parissenti AM (2004) Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Breast Cancer Res Treat 85:31-51. (Pubitemid 38437981)
8. Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, Johnson CS, Scott-Horton TJ, Li L, McLeod HL, et al. (2006) Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis. Clin Cancer Res 12:6094-6099. (Pubitemid 44703774)
9. Harrison M and Swanton C (2008) Epothilones and new analogues of the microtubule modulators in taxane-resistant disease. Expert Opin Investig Drugs 17:523-546. (Pubitemid 351578170)
10. Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, Hurtado de Mendoza F, et al. (2010) Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat 122:409-418.
11. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, and Schinkel AH (2005) MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 116:824-829. (Pubitemid 41099717)
12. Kapadnis S, Perloff ES, Khun W, Fox L, Crespi CL, and Stresser DM (2009) Assessment of P-gp, BCRP, and MRP activity in Caco-2 and MDR1-LLC-PK1 cell monolayers, at the 16th International Society for the Study of Xenobiotics North America Meeting; 2009 Oct. 18-22; Baltimore, MD. Abstract 359, International Society for the Study of Xenobiotics, Washington, DC.
13. Kars MD, Işeri OD, Ural AU, and Gündüz U (2007) In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells. Anticancer Res 27:4031-4037.
14. Krishnamurthy P and Schuetz JD (2006) Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol 46:381-410. (Pubitemid 43271195)
15. Kruh GD and Belinsky MG (2003) The MRP family of drug efflux pumps. Oncogene 22:7537-7552. (Pubitemid 37487175)
16. Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, and Schellens JH (2002) Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20:2943-2950. (Pubitemid 34728888)
17. Lagas JS, Vlaming ML, van Tellingen O, Wagenaar E, Jansen RS, Rosing H, Beijnen JH, and Schinkel AH (2006) Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res 12:6125-6132. (Pubitemid 44703778)
18. Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, and Vite G (2008) Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 63:157-166.
19. Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, and Kramer RA (2001) BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor activity. Clin Cancer Res 7:1429-1437. (Pubitemid 32708699)
20. Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW, Wiebesiek A, Vite G, Fairchild CR, and Kramer R (2009) Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 63:201-212.
21. Lehnert M, Emerson S, Dalton WS, de Giuli R, and Salmon SE (1993) In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance. J Natl Cancer Inst Monogr 15:63-67.
22. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, and Bates SE (2000) The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113:2011-2021. (Pubitemid 30386505)
23. Maliepaard M, van Gastelen MA, Tohgo A, Hausheer FH, van Waardenburg RC, de Jong LA, Pluim D, Beijnen JH, and Schellens JH (2001) Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 7:935-941. (Pubitemid 32708732)
24. Malingré MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Ten Bokkel Huinink WW, Schot ME, and Schellens JH (2001) Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 19:1160-1166. (Pubitemid 32176294)
25. McDaid HM, Mani S, Shen HJ, Muggia F, Sonnichsen D, and Horwitz SB (2002) Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res 8:2035-2043. (Pubitemid 34753571)
26. McGrogan BT, Gilmartin B, Carney DN, and McCann A (2008) Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 1785:96-132.
27. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke- Pearson DL, and Davidson M (1996) Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: A phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 23(5 Suppl 12):40-47. (Pubitemid 26391379)
28. Meerum Terwogt JM, Malingré MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman FJ, van Tellingen O, Swart M, and Schellens JH (1999) Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 5:3379-3384.
29. Rabindran SK, Ross DD, Doyle LA, Yang W, and Greenberger LM (2000) Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60:47-50. (Pubitemid 30058728)
30. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS, and Bates SE (2003) Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89:1971-1978. (Pubitemid 37533279)
31. Robey RW, Polgar O, Deeken J, To KW, and Bates SE (2007) ABCG2: Determining its relevance in clinical drug resistance. Cancer Metastasis Rev 26:39-57. (Pubitemid 46452182)
32. Rothermel J, Wartmann M, Chen T, Hohneker J (2003) EPO906 (epothilone B): A promising novel microtubule stabilizer. Semin Oncol 30(3 Suppl 6):51-55. (Pubitemid 36712859)
33. Rowinsky EK (1997) The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48:353-374. (Pubitemid 27101837)
34. Shirakawa K, Takara K, Tanigawara Y, Aoyama N, Kasuga M, Komada F, Sakaeda T, and Okumura K (1999) Interaction of docetaxel ("Taxotere") with human P-glycoprotein. Jpn J Cancer Res 90:1380-1386. (Pubitemid 30032078)
35. Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, et al. (2010) Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 28:3256-3263.
36. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, and van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035. (Pubitemid 27113956)
37. Vahdat L (2008) Ixabepilone: A novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist 13:214-221. (Pubitemid 351679896)
38. Vander Borght S, Libbrecht L, Katoonizadeh A, van Pelt J, Cassiman D, Nevens F, Van Lommel A, Petersen BE, Fevery J, Jansen PL, et al. (2006) Breast cancer resistance protein (BCRP/ABCG2) is expressed by progenitor cells/reactive ductules and hepatocytes and its expression pattern is influenced by disease etiology and species type: Possible functional consequences. J Histochem Cytochem 54:1051-1059. (Pubitemid 44298592)
39. Wani MC, Taylor HL, Wall ME, Coggon P, and McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325-2327.